SENESCENCE TREATMENT with IL-15-BASED FUSIONS to IL-7 and IL-21
AssigneeAltor BioScience Corporation
InventorHing C. Wong
Life of this patent
Estimating the term…
Abstract
The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-7 or IL-21.
Claims20
1-60. (canceled)
A method of treatment of a senescent cell-related disease in a subject in need thereof, the method comprising ex vivo treatment of immune cells with an isolated soluble fusion protein complex comprising at least two fusion proteins, wherein:
- a first fusion protein comprises interleukin-7 (IL-7) (SEQ ID NO:10) and interleukin-15 receptor alpha sushi-binding domain/Fc (IL-15RαSu/Fc) (SEQ ID NO:8), and
- a second fusion protein comprises interleukin-21 (IL-21) (SEQ ID NO:6) and an IL-15 variant comprising an N72D mutation (IL-15N72D) (SEQ ID NO:12) or human wild-type IL-15;
- wherein the IL-15 domain of the second fusion protein binds to the IL-15RαSu domain of the first fusion protein to form a soluble fusion protein complex;
- wherein the immune cells are thereby activated and formulated for administration to the subject;
- and
- wherein the immune cells are administered to the subject.
A method of treatment of a senescent cell-related disease in a subject in need thereof, the method comprising administering to the subject an effective amount of an isolated soluble fusion protein complex comprising:
- a first fusion protein comprising interleukin-7 (IL-7) (SEQ ID NO:10) and interleukin-15 receptor alpha sushi-binding domain/Fc (IL-15RαSu/Fc) (SEQ ID NO:8);
- and
- a second fusion protein comprising interleukin-21 (IL-21) (SEQ ID NO:6) and an IL-15 variant comprising an N72D mutation (IL-15N72D) (SEQ ID NO:12) or human wild-type IL-15;
- and
- wherein the IL-15 domain of the second fusion protein binds to the IL-15RαSu domain of the first fusion protein to form a soluble fusion protein complex.
A method of treatment of a senescent cell-related disease in a subject in need thereof, the method comprising administering to the subject an effective amount of an isolated soluble fusion protein complex comprising:
- a first fusion protein comprising interleukin-21 (IL-21) (SEQ ID NO:6) and interleukin-15 receptor alpha sushi-binding domain/Fc (IL-15RαSu/Fc) (SEQ ID NO:8);
- and
- a second fusion protein comprising interleukin-7 (IL-7) (SEQ ID NO:10) and an IL-15 variant comprising an N72D mutation (IL-15N72D) (SEQ ID NO:12) or human wild-type IL-15;
- and
- wherein the IL-15 domain of the second fusion protein binds to the IL-15RαSu domain of the first fusion protein to form a soluble fusion protein complex.
Dependencies are inferred from the claim text.